Patients With Metastatic Pancreatic Cancer Who Reported Higher Daily Step Counts Had Greater QoL on SM-88

Published by W Butcher on

A preliminary exploratory analysis from part 2 of the phase 2/3 TYME-88-Panc trial (NCT03512756) of SM-88 (racemetyrosine) in patients with metastatic pancreatic cancer showed a correlation between mean daily step count during the first 2 weeks of treatment and self-reported quality of life (QoL), according to data reported at the 2021 ASCO Gastrointestinal Cancers Symposium.

Read More…

Categories: Uncategorized

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published.